Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Stocks in this Quantisnow insightIndustrials
Historical context for BRKR
Across the 24 sessions after earlier BRKR headlines, the stock closed higher 16 times and lower 8 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BRKR | SPY |
|---|---|---|---|
| May 26, 2026 | Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI | +2.7% | +0.7% |
| May 6, 2026 | Bruker Reports First Quarter 2026 Financial Results | +11.3% | +1.4% |
| Apr 24, 2026 | Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast | +0.9% | +0.8% |
| Apr 17, 2026 | Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026and 2 other headlines that session | +4.5% | +1.2% |
| Apr 13, 2026 | Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026 | +3.9% | +1.0% |
| Apr 7, 2026 | Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research | -0.2% | +0.0% |
Keep researching BRKR
Quantisnow market dataNASDAQ
BRKR
Bruker Corporation
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
Get push alerts for BRKR
Full BRKR profile on Quantisnow Follow BRKR and get a push notification the moment its next story breaks.